Docket Number:28A-961219
Inventor:Chi-Huey Wong, Jim-Min Fang, Jiun-Jie Shie, Yih-Shyun Edmond Cheng, Jia-Tsrong Jan
IP Status:US 7888337 B2、AU 2008292859、JP 5509080、CN ZL200880113461.2、CA 2697837、EP 2190439、KR 10-1535691、TW Trademark
Abstract:
The invention relates to an efficient and flexible synthesis of Tamiflu and the highly potent neuraminidase inhibitor Tamiphosphor that were achieved in 11 steps and > 20% overall yields from the readily available fermentation product (1S-cis)-3-bromo-3,5-cyclohexadiene-1,2-diol. The key transformations include an initial regio- and stereoselective bromoamidation of a bromoarene cis-dihydrodiol, as well as the final palladium-catalyzed carbonylation and phosphonylation. Ever since the first highly pathogenic H5N1 virus was isolated in 1996, human cases of avian influenza have been reported throughout the world. We reported an anti-influenza drug candidate named "Tamiphosphor" in September 2007, and continued working on the improvement of procedures and effectiveness of this compound. Tamiflu is an orally available anti-H5N1/H1N1 drug to date. Drug resistance will be inevitable. Tamiphosphor functions as an inhibitor toward the neuraminidase active site of the virus, so does Tamiflu. Yet, Tamiphosphor proves to be more effective due to its higher affinity in the enzyme inhibition. Survival rate of infected mice treated with Tamiphosphor as well as symptoms of recovery all showed better result. Therefore, it possesses great potential as an oral anti-influenza drug.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you
